Foamix reaches litigation settlement with Teva on Finacea Foam
Foamix, a specialty pharmaceutical company, and LEO Pharma have entered into a settlement and license agreement with an affiliate of Teva to resolve pending patent litigation involving Finacea Foam.
Details of the settlement agreement are confidential, and the settlement agreement is subject to the review of the Federal Trade Commission and the U.S. Department of Justice.
This settlement comes after the settlement in April 2019 with affiliates of Perrigo relating to Finacea Foam.
“Together with LEO Pharma, we are pleased to have now also settled the outstanding litigation with Teva,” said David Domzalski, Foamix CEO. “We will continue to vigorously defend our patents and explore opportunities to further expand our intellectual property portfolio around our proprietary foam products and technologies.”
Foamix is the owner of patents that have been licensed to LEO Pharma to market Finacea Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea.
Foamix’s recently approved product Amzeeq (minocycline) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris, and its product candidates FMX103 and FCD105, are based on a different foam technology platform and different patents than those listed in the Orange Book for the foam technology used in Finacea Foam.
Patent infringement litigation related to Finacea Foam continues against Taro.